Phase III results on contraceptive gel published in journal

15 July 2020

The reproductive health journal Contraception has published results from the Phase III AMPOWER study evaluating Phexxi (lactic acid, citric acid and potassium bitartrate) for the prevention of pregnancy.

Phexxi, from Evofem Biosciences (Nasdaq: EVFM), is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm.

"We look forward to the commercial launch in September and the opportunity to provide an innovative option to the more than 17 million women in the USA who are fed up with hormonal contraception"It was approved by the US Food and Drug Administration on May 22 this year for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception based on the results of the Phase III AMPOWER study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK